Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Treatment and Pharmacology, Breast Cancer Treatment Studies, BRCA gene mutations in cancer, and PARP inhibition in cancer therapy.
NCCN Guidelines® Insights: Breast Cancer, Version 5.2025
Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023
Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline <i>BRCA1</i> - or <i>BRCA2</i> -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
SWOG S0307 phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: Comparison of toxicities and patient-stated preference for oral versus intravenous delivery.
Proteomic Response to Acupuncture Treatment in Spontaneously Hypertensive Rats